RE:L’analyste de la RBC cesse sa couverture - Les Affaires
difficulties in meeting operational objectives??
1)REPLAZIM CMC activities are expected to be completed at the end of 2019 setting the drug up for introduction in 2020,
2)two major transactions in progress (lazard),
3)NASDAQ registration in the fall,
4)Pivotal Phase 3 clinical trial design finalized to support regulatory submissions in the U.S. and Europe,
5)Opens an efficient route to market for PBI-4050 and potential to monetize Prometic's second PRV!
He could not find a better reason to leave....loll
Bio